Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search



You are here Haematology > Our Research > Publications

Our Publications

Show: AllPeer ReviewedNon Peer Reviewed
23 publications from 2022

Schetelig J., Chevallier P., van Gelder M., Hoek J., Hermine O., Chakraverty R., Browne P., Milpied N., Malagola M., Socie G., Delgado J., Deconinck E., Damaj G., Maury S., Beelen D., Quoc S.N., Shankara P., Brecht A., Mayer J., Hunault-Berger M., Bittenbring J., Thieblemont C., Lepretre S., Baldauf H., de Wreede L.C., Tournilhac O., Yakoub-Agha I., Kroger N., Dreger P., Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party (Bone Marrow Transplantation, (2021), 56, 3, (605-613), 10.1038/s41409-020-01069-w), Bone Marrow Transplantation, 57, (2), 2022, p330-
Journal Article; Published; Peer Reviewed; Author Profile: BROWNPV; DOI

Waszczuk-Gajda A., Penack O., Sbianchi G., Koster L., Blaise D., Remenyi P., Russell N., Ljungman P., Trneny M., Mayer J., Iacobelli S., Kobbe G., Scheid C., Apperley J., Touzeau C., Lenhoff S., Jantunen E., Anagnostopoulos A., Paris L., Browne P., Thieblemont C., Schaap N., Sierra J., Yakoub-Agha I., Garderet L., Styczynski J., Schoemans H., Moiseev I., Duarte R.F., Peric Z., Montoto S., van Biezen A., Mikulska M., Aljurf M., Ruutu T., Kroger N., Morris C., Koenecke C., Schoenland S., Basak G.W., Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study, Journal of Clinical Medicine, 11, (12), 2022
Journal Article; Published; Peer Reviewed; Author Profiles: LYNAMLN BROWNPV ; DOI

Masouridi-Levrat S, Olavarria E, Iacobelli S, Aljurf M, Morozova E, Niittyvuopio R, Sengeloev H, Reményi P, Helbig G, Browne P, Ganser A, Nagler A, Snowden JA, Robin M, Passweg J, Van Gorkom G, Wallet HL, Hoek J, Blok HJ, De Witte T, Kroeger N, Hayden P, Chalandon Y, Agha IY., Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT., Bone marrow transplantation, 57, (1), 2022, p23-30
Journal Article; Published; Peer Reviewed; Author Profiles: HAYDENP BROWNPV LYNAMLN ; DOI

Czerw T, Iacobelli S, Malpassuti V, Koster L, Kröger N, Robin M, Maertens J, Chevallier P, Watz E, Poiré X, Snowden JA, Kuball J, Kinsella F, Blaise D, Reményi P, Mear JB, Cammenga J, Rubio MT, Maury S, Daguindau E, Finnegan D, Hayden P, Hernández-Boluda JC, McLornan D, Yakoub-Agha I., Impact of donor-derived CD34"+"infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (2), 2022, p261-270
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Chabannon C, Ciceri F, Corbacioglu S, Ellard R, Sanchez-Guijo F, Jäger U, Hildebrandt M, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Rees J, Rioufol C, Saccardi R, Snowden JA, Styczynski J, Subklewe M, Thieblemont C, Topp M, Ispizua ÁU, Chen D, Vrhovac R, Gribben JG, Kröger N, Einsele H, Yakoub-Agha I., Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)., Annals of oncology : official journal of the European Society for Medical Oncology, 33, (3), 2022, p259-275
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M., Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT., Bone marrow transplantation, 57, (3), 2022, p499-501
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Hernández-Boluda JC, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub-Agha I., Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT., Bone marrow transplantation, 57, (3), 2022, p416-422
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, Nicholson E, Rabin N, Touzeau C, Byrne J, Huynh A, Cornelissen JJ, Potter V, Forcade E, Parrish C, Gribben J, Chretien ML, Mielke S, Gedde-Dahl T, Reményi P, Tsirigotis P, Garcia Guiñón A, Beksac M, Schönland S, Yakoub-Agha I., Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019., British journal of haematology, 197, (1), 2022, p82-96
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Drozd-Soko"owska J, Gras L, Zinger N, Snowden JA, Arat M, Basak G, Pouli A, Crawley C, Wilson KMO, Tilly H, Byrne J, Bulabois CE, Passweg J, Ozkurt ZN, Schroyens W, Lioure B, Colorado Araujo M, Poiré X, Van Gorkom G, Gurman G, de Wreede LC, Hayden PJ, Beksac M, Schönland SO, Yakoub-Agha I., Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT., Bone marrow transplantation, 57, (4), 2022, p633-640
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

O'Gorman P, Laubach JP, O'Dwyer ME, Krawczyk J, Yee AJ, Gilligan O, Cahill MR, Rosenblatt J, Quinn J, Murphy PT, DiPietro H, Perera MR, Crotty GM, Cummings K, Hayden PJ, Browne P, Savell A, O'Leary HM, O'Keeffe D, Masone K, Hennessy BJ, Guerrero Garcia T, Scott K, Saeed K, Bianchi G, Dowling P, Tierney C, Richardson PG., Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma., American journal of hematology, 97, (5), 2022, p562-573
Journal Article; Published; Peer Reviewed; Author Profiles: HAYDENP BROWNPV LYNAMLN ; DOI

Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, Koster L, Ganser A, Volin L, Sengeloev H, Michallet M, Tischer J, Jindra P, Cascon MJP, Koc Y, Arat M, Tomaszewska A, Hayden P, de Witte T, Yakoub-Agha I, Kröger N, Robin M., Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (5), 2022, p768-774
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legie" W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špi"ka I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, ELOQUENT-1 investigators., Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial., The Lancet. Haematology, 9, (6), 2022, pe403-e414
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Hernández-Boluda JC, Pereira A, Zinger N, Gras L, Martino R, Nikolousis E, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub-Agha I., Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT., Bone marrow transplantation, 57, (6), 2022, p1051
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Onida F, Sbianchi G, Radujkovic A, Sockel K, Kröger N, Sierra J, Socié G, Cornelissen J, Poiré X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub-Agha I., Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP., Bone marrow transplantation, 57, (6), 2022, p896-902
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, Finke J, Passweg J, Cornelissen J, Schub N, Veelken JH, Beguin Y, Wilson K, Zuckerman T, Hunault-Berger M, Lioure B, Porras RP, Turlure P, Kerre T, Koster L, Hayden PJ, Onida F, Scheid C, Chalandon Y, Robin M, Yakoub-Agha I., Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (7), 2022, p1072-1078
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

McLornan DP, Gras L, Martin I, Sirait T, Schroeder T, Blau IW, Kuball J, Byrne J, Collin M, Stadler M, Desmier D, Salmenniemi U, Jindra P, Mikhailova N, Lenhoff S, Rifón J, Robin M, Rovira M, Veelken H, Sadowska-Klasa A, Zecca M, Hayden PJ, Czerw T, Hernández-Boluda JC, Yakoub-Agha I., Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT., British journal of haematology, 198, (1), 2022, p209-213
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Dholaria B, Radujkovic A, Estrada-Merly N, Sirait T, Kim S, Hernández-Boluda JC, Czerw T, Hayden PJ, Kansagra A, Ho VT, Nishihori T, Shaughnessy P, Scott B, Nakamura R, Oran B, Kharfan-Dabaja M, Savani BN, McLornan D, Yakoub-Agha I, Saber W., Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis., British journal of haematology, 198, (4), 2022, p785-789
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, Nazha A, Beelen DW, Rampal RK, Sockel K, Komrokji RS, Gagelmann N, Eikema DJ, Radujkovic A, Finke J, Potter V, Killick SB, Legrand F, Solary E, Broom A, Garcia-Manero G, Rizzoli V, Hayden P, Patnaik MM, Onida F, Yakoub-Agha I, Itzykson R., Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis., Blood, 140, (12), 2022, p1408-1418
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Gagelmann N, Sureda A, Montoto S, Murray J, Bolaños N, Kenyon M, Beksac M, Schönland S, Hayden P, Scheurer H, Morgan K, Garderet L, McLornan DP, Ruggeri A., Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper., The Lancet. Haematology, 9, (10), 2022, pe786-e795
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Chihara D, Gras L, Zinger N, Kröger N, Mayer J, Passweg J, De Latour RP, Byrne J, Krüger W, Bohn JP, Platzbecker U, Blau IW, Bonifazi F, Helbig G, McDonald A, Mistrik M, Mohty M, Ram R, Sanz J, Llamas CV, Kreitman RJ, Hayden PJ, McLornan D, Tournilhac O, Van Gelder M, Yakoub-Agha I., Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience., Haematologica, 2022
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Koenecke C, Eikema DJ, Hazelaar S, Schroeder T, Potter V, Kröger N, Bornhäuser M, Finke J, Platzbecker U, Radujkovic A, Ganser A, Salmenniem U, Blaise D, Kobbe G, Meijer E, Friis L, Maertens J, Caballero D, Cornelissen JJ, Olivieri A, Gulsum O, Hayden PJ, Onida F, Robin M, Yakoub-Agha I., Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT., Bone marrow transplantation, 57, (10), 2022, p1607-1611
Journal Article; Published; Peer Reviewed; Author Profile: HAYDENP; DOI

Rebecca Amet, Viola Previtali, Helene B. Mihigo, Emily Sheridan, Sarah Brophy , Nadhim Kamil Hante, Maria Jose Santos-Martinez, Patrick J. Hayden, Paul V. Browne, Isabel Rozas, Anthony M. McElligott , Daniela M. Zisterer , A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma , Life Sciences, 290, 2022
Journal Article; Published; Peer Reviewed; Author Profiles: LYNAMLN DZISTRER ROZASI HAYDENP MCELLIGA BROWNPV ; DOI

Townsend L, Dyer AH, Naughton A, Imangaliyev S, Dunne J, Kiersey R, Holden D, Mooney A, Leavy D, Ridge K, Sugrue J, Aldoseri M, Kelliher JH, Ní Cheallaigh C, Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression, Heliyon, 8, (4), 2022, pe09230 - e09236
Journal Article; Published; Peer Reviewed; Author Profiles: LYNAMLN BROWNPV NBOURKE DYERAD DGBYRNE MCLOUGRM ARWHITE NICHEAC2